Full Archive

Diabesity Wins

fWe’re not sure who coined the phrase diabesity, but it appropriately describes what Lilly and Novo Nordisk have become. These two legacy companies are no longer in the business of diabetes alone and are now as equally focused on obesity therefore they are diabesity companies. Yes, as we noted in a previous post not that long ago the fight against fat is fattening the bottom lines of Novo and Lilly. Look...

Fast reaction

It didn’t take long for the street to react to Tandem’s results when they DECREASED full year sales guidance lowering it from $850 million to $865 million to $835 million to $845 million. During the call the company cited three factors that contributed to the reduction in guidance. 1. COVID/Staffing issues in endocrinologists offices 2. Competition 3. Inflation While issues 1 and 3 will change competition will not and one has to wonder whether...

This is a joke

“The need for affordable insulin is urgent, especially for uninsured populations,” said Heather Cianfrocco, CEO of Optum Rx, in a statement. “By working with Sanofi, we will improve access and lower costs for people who need this life-saving medication.” This statement comes from an article posted on Fierce Healthcare about the alliance between Sanofi and Optum to offer a 30-day supply of insulin for $35. This just the latest in a...

Way wacky

Not sure when we started calling this the wacky world of diabetes, but the phrase is very appropriate and continues to be proven each day. Today’s wacky items include 1. Dexcom shares recover from sell off. 2. Insulet announces full market release of Omnipod 5. 3. Tandem, Lilly, Novo Nordisk and Insulet all report this week. As we write shares of Dexcom are up nearly 4% which we anticipated. The company reported results last...

Simple Math

After some raucous after-hours trading shares of Dexcom at the moment are down a rather muted 6%. As we noted yesterday this was expected and, in our opinion, creates a buying opportunity. For all the pontificating when it comes to CGM the math is quite simple and we see Dexcom having a major advantage. Here’s why. The Control IQ from Tandem and the Omnipod 5 from Insulet both work with the...

Been here before

First let’s get the big news out of the way as Dexcom this afternoon stated that the much-awaited G7 should be here by the end of the year with a full-blown launch in the first quarter of 2023. The other big news is a share repurchase plan. This as Momma Kliff would say was the good news. While we wouldn’t characterize results as the bad news but there is no...

Strange but true meets told you so

It really is difficult not to gloat just a little regarding Teladoc and their very ill-fated decision to value Livongo at $19 Billion dollars. As once again this very stupid decision has come back to bite them squarely in the ass as the company announced they were taking another $3 billion charge after taking a $6.3 billion charge in the first quarter. At the moment shares are down over 22%...